3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
13
Gynecologic
3
Breast
2
Head & Neck
1
Genitourinary
1
CNS
1
Conditions
Brain Neoplasms
3
Paraganglioma, Extra-Adrenal
2
Neoplasms
2
Glioma
2
Central Nervous System Neoplasms
2
Carcinoma, Renal Cell
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Rhabdomyosarcoma
1
Recurrence
1
Pheochromocytoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Meningeal Carcinomatosis
1
Melanoma
1
Glioblastoma
1
Colorectal Neoplasms
1
Carcinoma, Medullary
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
5
Docetaxel
4
ulixertinib
2
Trastuzumab
2
Radiotherapy
2
Paclitaxel
2
Oxaliplatin
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Irinotecan
2
Fluorodeoxyglucose F18
2
Carboplatin
2
Capecitabine
2
Bevacizumab
2
trastuzumab biosimilar HLX02
1
trametinib
1
tipifarnib
1
temsirolimus
1
tanespimycin
1
spartalizumab
1
sonidegib
1
sargramostim
1
sapanisertib
1
relatlimab
1
regorafenib
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
lenvatinib
×
CNS
×
Clear all
NCT03797326
2026-05-04
LEAP-005
Merck Sharp & Dohme LLC
Phase 2
Completed
611 enrolled
27 charts